The US Food and Drug Administration approved Narcan, a nasal spray formulation of naloxone, for sale as an over-the-counter (OTC) medication in March 2023. The purpose of OTC approval was to improve naloxone accessibility to reduce opioid overdoses; however, research has not yet evaluated whether naloxone's availability and cost changed since this policy was implemented.
No takes yet. Share an insight, caveat, or question.
Marley et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: